|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM338682325 |
| 003 |
DE-627 |
| 005 |
20231226001221.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.108984
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1128.xml
|
| 035 |
|
|
|a (DE-627)NLM338682325
|
| 035 |
|
|
|a (NLM)35338000
|
| 035 |
|
|
|a (PII)S1521-6616(22)00065-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a De Greef, Axel
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Pandemic chilblains
|b Are they SARS-CoV-2-related or not?
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.04.2022
|
| 500 |
|
|
|a Date Revised 03.01.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The exact etiopathology of chilblains observed during the Coronavirus Disease 2019 (COVID-19) pandemic is still unclear. Initially, SARS-CoV-2 appeared as the obvious causing agent, but two years of various investigations have failed to convincingly support its direct implication. Most affected individuals have no detectable virus, no anti-SARS-CoV-2 antibodies and no symptoms of COVID-19. Analyses of skin biopsies similarly failed to unambiguously demonstrate presence of the virus or its genome. In a recent hypothesis, SARS-CoV-2 would cause the lesions before being promptly eliminated by unusually strong type I interferon responses. With others, we feel that environmental factors have not been sufficiently considered, in particular cold exposure related to unprecedented containment measures. The cause of pandemic chilblains remains a stimulating puzzle which warrants further investigation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Chilblains
|
| 650 |
|
4 |
|a Cold
|
| 650 |
|
4 |
|a Pandemic
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
4 |
|a Trigger
|
| 650 |
|
4 |
|a Type 1 interferon
|
| 700 |
1 |
|
|a Coulie, Pierre G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Baeck, Marie
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 237(2022) vom: 25. Apr., Seite 108984
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:237
|g year:2022
|g day:25
|g month:04
|g pages:108984
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.108984
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 237
|j 2022
|b 25
|c 04
|h 108984
|